CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

December 18, 2024 12:05 PM

SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.Dear Shareholders,As 2024 draws to a close, I...

Read more

Mentavi Health Expands Therapy Offerings to More Than 40 States 

December 18, 2024 10:45 AM

Mentavi Health, a leading online provider of mental health diagnosis and treatment and a pioneer in telehealth services through ADHD Online, has expanded its telehealth therapy service to more than 40 states across the country. All therapy will be provided by doctorate-level psychologists, offering patients expert-level care for ADHD, anxiety, depression, and other conditions. These are the same psychologists who review and provide diagnosis via...

Read more

Harris Data Integrity Solutions Taps Julie Pursley as Director of Industry Relations

December 18, 2024 10:30 AM

NIAGARA FALLS, NY / ACCESSWIRE / December 18, 2024 / Harris Data Integrity Solutions, the leading provider of best-in-class person data integrity services and software, announced today the appointment of Julie Pursley, MSHI, RHIA, CHDA, FAHIMA, as its director of industry relations. In this role, which oversees all facets of sales activities, Pursley will focus on building team and client success and business operational efficiencies through a...

Read more

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

December 18, 2024 10:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of MVID in pediatric patients, has been initiated."The initiation of this double blind, placebo-controlled study in...

Read more

PharmPix Corp. Joins Forces With Mark Cuban Cost Plus Drug Company to Revolutionize Pharmacy Benefits

December 18, 2024 10:00 AM

Millions of patients nationwide will soon benefit from unprecedented cost transparency in their medications, thanks to a new alliance between PharmPix and Mark Cuban Cost Plus Drug Company (Cost Plus Drugs). With over 90% of prescribed drugs in the U.S. being generics, PharmPix and Cost Plus Drugs are taking bold steps to ensure transparency and affordability within the pharmacy benefits arena.PharmPix - Make an Impact PharmPix, leveraging...

Read more

One Community at a Time: Enabling Early Lung Cancer Detection Across the U.S.

December 18, 2024 9:45 AM

Originally published on Bristol Myers Squibb News & PerspectivesNORTHAMPTON, MA / ACCESSWIRE / December 18, 2024 / This year brings renewed hope to the fight against lung cancer because the public health community has the tools they need to turn the tide - and they are already seeing the results in action.Early detection through screening is key to improving lung cancer survivorship - when lung cancer is discovered early enough to be surgically...

Read more

Verisante Technology, Inc. Announces RTO Update:

December 18, 2024 9:30 AM

Verisante Technology, Inc. (TSX-V:VER.H) ("Verisante") announces that further to its news release dated October 31, 2024, SunRegen Healthcare AG ("SunRegen") has now closed the previously announced pre-RTO private placement.As announced on August 12, 2024, Verisante entered into a binding Letter of Intent ("LOI") to acquire a 100% interest in SunRegen Healthcare AG ("SunRegen"), a Swiss pharmaceutical company. The proposed transaction is a...

Read more

2025 Mobile EHR Global Report: Advancing Cloud-Based Digital Health Records in Europe. Africa and the Middle East – Black Book Research

December 18, 2024 9:30 AM

Black Book Research has unveiled its 2025 global survey findings on mobile electronic health record (EHR) usability, spotlighting the vendors at the forefront of mobile-first platform development. These platforms are redefining clinical functionalities and operational efficiency for healthcare organizations worldwide. The study, encompassing insights from nearly 14,000 EHR users across six continents, highlights the transformative role of mobile...

Read more

CordovaCann (CSE:CDVA)(OTCQB:LVRLF) Provides Year-End Update On Star Buds Cannabis Co. Retail Operations

December 18, 2024 9:30 AM

TORONTO, ON / ACCESSWIRE / December 18, 2024 / CordovaCann Corp. (CSE:CDVA)(OTCQB:LVRLF) ("Cordova" or the "Company"), a cannabis-focused consumer products company, proudly announces an update on its Star Buds Cannabis Co. retail operations in Canada.Star Buds Cannabis Co. stores produced strong results through the first two months of the quarter ending December 31, 2024 and are expected to sustain this growth through the final weeks of the...

Read more

Lexaria Forms New Scientific Advisory Board

December 18, 2024 9:25 AM

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board ("SAB") to assist in guiding Lexaria's rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry.The SAB will initially be comprised of four people and the Chairman of the SAB will be Lexaria's President and...

Read more

NeoPredics Welcomes Todd Usen as Chairman of the Board

December 18, 2024 9:00 AM

NeoPredics AG Switzerland, along with its subsidiaries NeoPredics AG Germany and NeoPredics USA Inc., is pleased to announce the appointment of Mr. Todd Usen as Chairman of the Board, marking an exciting new chapter for the company as it continues to grow its impact in maternal and neonatal healthcare. We extend our heartfelt gratitude to Dr. Volker Pfahlert, who has stepped down after four years of dedicated service. Under his leadership,...

Read more

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

December 18, 2024 9:00 AM

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an...

Read more

Interactive Strength Inc. (Nasdaq:TRNR) Secures 162 Unit CLMBR Commitment and Signs Exclusive Distribution Agreement With Planet Fitness SAS for France

December 18, 2024 8:00 AM

Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French RegionsFrance is the Second-Largest Fitness Market in the EUAUSTIN, TX / ACCESSWIRE / December 18, 2024 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced it secured exclusive distribution in Metropolitan France and French...

Read more

The Naderi Center for Plastic Surgery and Dermatology Reveals Updated Website for Virginia and Maryland Patients

December 18, 2024 8:00 AM

The Naderi Center for Plastic Surgery and Dermatology is pleased to introduce the newly updated website for the practice, now available to patients in the greater Washington DC area, Virginia and Maryland. The revamped site offers information about the center's surgical and non-surgical procedures, focusing on facial plastic surgery, rhinoplasty, dermatology and skincare. This platform highlights the skills of the center's board-certified...

Read more

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

December 18, 2024 8:00 AM

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.Dear Shareholders,As 2024 draws to a close, I am honored to share Ainos, Inc.'s significant...

Read more

CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization

December 18, 2024 8:00 AM

CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.This monumental share...

Read more

Global Hospital Capacity Management Solutions Market to Reach USD 1,808.9 Million by 2034, Driven by A 5.1% CAGR Amid Rising Demand for Operational Efficiency | Future Market Insights, Inc.

December 18, 2024 7:30 AM

The Hospital Capacity Management Solutions Market is poised to grow significantly between 2024 and 2034, with the market size projected to expand from USD 1,156.1 million in 2024 to USD 1,808.9 million by 2034, reflecting a compound annual growth rate (CAGR) of 5.1%. This growth is driven by increasing global healthcare demands and the critical need for efficient resource utilization within hospitals.Healthcare systems worldwide are under...

Read more

Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01

December 18, 2024 2:20 AM

LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according to plan in the company's Phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201. The study's independent Data Monitoring Committee (DMC) is expected to be able to present its analysis of the patient group during the first quarter. A...

Read more

Onyx Ranked #1 for Client Satisfaction in FHIR-Based Prior Authorization Solutions

December 17, 2024 4:30 PM

Black Book Research has identified Onyx as the highest-rated vendor in its 2025 survey on FHIR-based prior authorization interoperability solutions. The survey, which captured insights from 665 providers and 718 payers, highlights the importance of CMS-mandated HL7\u00ae FHIR\u00ae (Fast Healthcare Interoperability Resources) standards in modernizing healthcare data exchange. The study underscores the essential role of FHIR-based APIs in...

Read more

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

December 17, 2024 4:05 PM

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company's GMP manufacturing facility is available for viewing via slideshow on the Presentations page of the Investor Relations portion of the Company's website. The Company's Form 10-K can be viewed on...

Read more